TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Analyst Ratings
USA - NYSE:TEVA - US8816242098 - ADR
24.46 USD
-0.14 (-0.57%)
24.12 USD
-0.34 (-1.39%)
ChartMill assigns a Buy % Consensus number of 42% to TEVA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 0.06. This target is -99.77% below the current price.
TEVA was analyzed by 9 analysts. The buy percentage consensus is at 42. So analysts seem to be rather negative about TEVA.
In the previous month the buy percentage consensus was at a similar level.
TEVA was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-24 | UBS | Maintains | Buy -> Buy |
| 2025-06-26 | UBS | Maintains | Buy -> Buy |
| 2025-06-06 | Goldman Sachs | Initiate | Buy |
| 2025-05-28 | Truist Securities | Initiate | Buy |
| 2025-05-12 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-05-08 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-06 | B of A Securities | Maintains | Buy -> Buy |
| 2025-01-30 | UBS | Maintains | Buy -> Buy |
| 2025-01-30 | Barclays | Maintains | Overweight -> Overweight |
| 2025-01-23 | UBS | Maintains | Buy -> Buy |
| 2025-01-17 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-12-18 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-23 | Barclays | Maintains | Overweight -> Overweight |
| 2024-10-21 | JP Morgan | Maintains | Neutral -> Neutral |
| 2024-09-03 | UBS | Maintains | Buy -> Buy |
| 2024-08-01 | Barclays | Maintains | Overweight -> Overweight |
| 2024-07-10 | UBS | Maintains | Buy -> Buy |
| 2024-06-27 | Jefferies | Maintains | Buy -> Buy |
| 2024-06-05 | Barclays | Maintains | Overweight -> Overweight |
| 2024-05-30 | B of A Securities | Maintains | Buy -> Buy |
| 2024-05-13 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-05-09 | Barclays | Maintains | Overweight -> Overweight |
| 2024-03-08 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-02-12 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-02-05 | Barclays | Maintains | Overweight -> Overweight |
| 2024-02-05 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-01-29 | Barclays | Maintains | Overweight -> Overweight |
| 2024-01-23 | Jefferies | Upgrade | Hold -> Buy |
| 2024-01-03 | Piper Sandler | Upgrade | Underweight -> Neutral |
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What is the price target for TEVA stock?
9 analysts have analysed TEVA and the average price target is 0.06 USD. This implies a price decrease of -99.77% is expected in the next year compared to the current price of 24.46.
Can you provide the consensus rating for TEVA PHARMACEUTICAL-SP ADR stock?
The consensus rating for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 42.2222 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
How many analysts cover TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
The number of analysts covering TEVA PHARMACEUTICAL-SP ADR (TEVA) is 9.